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Summary
Background The rise in atopic diseases has been linked to disturbances in the intestinal
microbiota composition.
Objective The purpose of this study was to investigate the intestinal microbiota composition in
infants in whom atopic (IgE-associated) eczema was or was not developing, using a molecular
fingerprinting technique.
Methods Within a prospective birth cohort study, fecal samples have been collected at the
infant’s age of 1 month. Within the context of this cohort, we conducted a nested case–control
study comparing fecal samples of 26 infants who became sensitized and developed eczema
within the first year of life with 52 non-sensitized non-eczematous infants. The composition
of the fecal samples was examined using PCR combined with denaturing gradient gel
electrophoresis. Using real-time PCR, total bacterial counts and bifidobacterial counts were
enumerated.
Results Neither total bacterial profiles nor the type and proportion of bifidobacteria in the
feces were associated with the development of atopic eczema. The similarity of bacterial
profiles was low; mean similarity was approximately 33% in both infants with or without
atopic eczema. The prevalence of one specific band in total bacterial profiles was significantly
higher in infants with atopic eczema compared with controls (96% vs. 71%, P= 0.01).
Identification of this band revealed that it represented Escherichia coli.
Conclusion Although no association was found between the development of IgE-associated
eczema and the dominant gut microbiota as a whole or with the bifdobacterial microbiota, the
association with E. coli indicates that differences in gut microbiota do precede the
development of atopy.
Keywords atopic eczema, DGGE, intestinal microbiota, nested case–control, 16S rRNA
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Introduction
Intestinal microorganisms have a major impact on the
development and functioning of the intestinal immune
system of the host, while the intestinal immune system
regulates the colonization of the gut by these microorgan-
isms. This interplay has been suggested to have a major
influence on the host even beyond the intestines [1]. For
example, the rise of atopic diseases has been linked to
disturbances in the composition of the gut microbiota [2].
Differences in intestinal microbiota have been described
between healthy and allergic children [3–5]. Furthermore,
in prospective studies, it has been shown that the differ-
ences in the gut microbiota composition are already
present before the development of allergic sensitization
and symptoms [6, 7].
Bifidobacteria are generally considered to be health-
beneficial and have been associated with a lower risk of
atopy [3, 4, 6, 7]. The effect of bifidobacteria seems,
however, to be species-dependent. In vitro studies have
shown that bifidobacterial species differentially affect the
production of cytokines by dendritic cells and macro-
phages [8, 9]. Furthermore, allergic infants have been
reported to harbour a more adult-type bifidobacterium
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flora containing Bifidobacterium adolescentis, whereas
healthy infants had high levels of the infant-type
B. bifidum [10].
Most studies on the gut microbiota and atopy were
based on the quantification of selected bacterial groups or
species that are commonly present in the intestines. The
following are some of the disadvantages of classical
culturing techniques: samples require immediate proces-
sing and extensive expertise, and specialized equipment is
needed to isolate strict anaerobes [11]. The introduction of
molecular techniques to study the gut microbiota has
overcome these problems, and using these techniques, it
now gives us the opportunity to analyse frozen samples
collected from large cohorts.
PCR combined with denaturing gradient gel electro-
phoresis (PCR-DGGE) is a genetic fingerprinting techni-
que, which provides a pattern or profile of the genetic
diversity in a microbial community. In this technique, it is
not required for the bacteria or their sequences to be
previously characterized [12]. In principle, PCR-DGGE can
be used to distinguish two (bacterial) DNA molecules that
differ from as little as a single-base substitution [13].
Murray et al. [14] used this technique to compare the gut
microbiota of sensitized wheezy and non-sensitized non-
wheezy infants aged 4 years. Although no differences
were found between cases and controls, the authors
concluded that further studies using molecular techniques
are necessary to establish whether differences between
fecal microbiota composition truly exist in younger aller-
gic and non-allergic children with different allergic dis-
eases [14].
In the present study, fecal samples collected at the age
of 1-month post-partum of infants in whom atopic
eczema was or was not developing within the first year of
life were compared using PCR-DGGE.
Material and methods
Subjects and samples
Within the prospective KOALA Birth Cohort Study on the
aetiology of allergic diseases, we conducted a nested
case–control study. The design of the cohort has been
described previously [15]. Briefly, from October 2000 to
December 2002, 2834 pregnant women were recruited at
14–18 weeks of gestation. Information on perinatal deter-
minants of the child’s health as well as on hygiene,
infections, nutrition, child rearing, other lifestyle charac-
teristics and on atopic manifestations were collected for
all members of the cohort by repeated questionnaires at 34
weeks of gestation and 3, 7, 12 months post-partum. In the
second part of the cohort (those participants recruited
from October 2002 onwards), parents were asked to collect
a fecal sample at the infant’s age of 1 month and to
consent to collecting of capillary blood for determination
of total and specific IgE at the infant’s age of 1 year.
For this nested case–control study, the selection criteria
were the availability of infant’s feces and capillary blood,
full term birth and no history of antibiotic use within the
first month of life. From those infants who met these
criteria, we selected infants who subsequently developed
atopic eczema, and randomly selected twice as many
control infants. Cases had to meet the following criteria:
(1) having an itchy relapsing rash during the first year of
life (parentally reported), excluding cases with only diaper
rash, rash around the eyes and/or scalp scaling; and (2)
being IgE sensitized (4 1 IU/mL) for cow’s milk, hen’s egg
or peanut at the age of 1 year. Control subjects were
randomly selected out of the infants without an itchy
relapsing rash during the first year of life and without
detectable specific IgE levels (o 0.36 IU/mL). Determina-
tion of specific IgE from capillary blood has been per-
formed as described previously [16, 17], with adjustments
made for testing in capillary blood [18].
Collection of infant’s feces
To collect feces at the infant’s age of 1 month, parents
received a feces tube with spoon attached to the lid
(Sarstedt, Nu¨mbrecht, Germany), together with a sanitary
napkin, an instruction form and a brief questionnaire
(feces questionnaire). Parents collected a fecal sample by
placing the sanitary napkin in the diaper (to prevent
absorption of the feces by the diaper) and collect the feces
out of the napkin into the collection tube and sent it,
together with the questionnaire, immediately to our la-
boratory by post. At the laboratory, fecal samples were
tenfold diluted in peptone–water (Oxoid CM0009, Basing-
stoke, UK) containing 20% v/v glycerol (Merck, Damstadt,
Germany) and stored at  20 1C until analysis.
DNA purification from feces
0.2mL of the diluted feces was added to a 2-mL vial
containing approximately 300mg glass beads (diameter
0.1mm) and 1.4mL of ASL-buffer from the QIAamp DNA
Stool Mini Kit (Qiagen, Hilden, Germany). The bacterial
samples were disrupted in a mini-bead beater (Biospec
Products, Bartlesville, OK, USA) at 5000 r.p.m. for 3min.
Subsequently, the bacterial DNA was isolated from the
samples using the QIAamp DNA Stool Mini Kit, according
to the instructions of the manufacturer. The DNA was
eluted in a final volume of 200 mL.
Denaturing gradient gel electrophoresis
All primers used in the study are listed in Table 1. Primers
968-GC-f and 1401-r were used to amplify the V6 to
V8 regions of bacterial 16S rRNA. Bifidobacterium
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genus-specific PCR was performed using 16S rDNA-tar-
geted primers Bif-164-f and Bif-662-GC-r. A 40-bp GC-
clamp was attached to the 50 end of primer 968-GC-f and
Bif-662-GC-r (Table 1) in order to facilitate the analysis of
the PCR products by DGGE.
PCR reactions were performed as described previously
[19, 20], using the HotStarTaq polymerase kit from Qia-
gen. The reaction mixtures contained 1 PCR buffer
(Qiagen), 3mM MgCl2, 0.2mM of each dNTP, 0.2 mM of each
primer, 1.25 U Taq polymerase and 5 mL of appropriately
diluted template DNA in a final volume of 50 mL. The PCR
thermocycling programme with primers 968-GC-f and
1401-r was the following: 94 1C for 5min; 35 cycles of
94 1C for 30 s, 53 1C for 20 s, 68 1C for 40 s and 68 1C for
7min. The reactions were subsequently cooled to 5 1C. The
annealing temperature was changed from 53 to 62 1C for
primers Bif-164-f and Bif-662-GC-r.
Analysis of PCR amplicons by DGGE was performed
essentially as described previously [19, 21], using the
DCode detection system (Bio-Rad, Hercules, CA, USA).
Polyacrylamide gels (8% w/v, acrylamide : bisacrylamide-
37.5 : 1) in 0.5 TAE with a denaturing gradient were
prepared with a gradient mixer and pump. The following
denaturing gradients were used: 45–65% for bacterial and
45–55% for bifidobacterial PCR products. A 100% dena-
turant corresponds to 7 M urea and 40% (v/v) formamide.
PCR amplicons were separated by electrophoresis at a
constant voltage of 85V and a temperature of 60 1C for
16 h. The DNA fragments were visualized by AgNO3
staining, as described previously [22]. Identification of
bacterial species represented in the bifidobacterial DGGE
profiles was based on the comparison with an identifica-
tion ladder consisting of control strains of B. breve, B.
bifidum, B. infantis, B. longum and B. adolescentis.
Identification of bands of interest in total bacterial profiles
was done by elution of DNA fragments from the gels
followed by sequencing [23]. Selected DGGE bands were
cut out of the gel with a sterile scalpel followed by elution
of the DNA by mechanically disrupting the gel slices and
resuspension in 50 mL H2O. Two microlitre of the eluted
DNA of each DGGE band was reamplified by using the
conditions described above (using primers 968-GC-f and
1401-r), after which PCR products were analysed by
DGGE, together with the amplicons of the original sam-
ples in order to verify that the correct bands were isolated.
Upon confirmation, PCR products were purified and
sequenced using primers 968-GC-f and 1401-r.
Quantification of bifidobacteria in fecal samples
For the enumeration of bifidobacteria and total bacterial
counts, samples were subjected to a quantitative real-time
PCR, as described previously [24]. Briefly, the 50 nuclease
chemistry was used for the quantification of bifidobacter-
ia with primers Bif-f and Bif-r and probe Bif-pr. The
SYBR-Green chemistry was used for the determination of
total bacterial counts using primers total-f and total-r.
Statistical analysis
Total bacterial profiles were compared using the GelCom-
par II software (Applied Maths, St-Martens-Latem,
Belgium). With this software, Dice’s similarity coefficients
were calculated, following the equation:
S ¼ ½2a=ðbþ cÞ  100%
where b is the number of PCR-DGGE bands in subject 1,
c is the number of PCR-DGGE bands in subject 2 and a is
the number of matching PCR-DGGE bands [25]. Compar-
ing the bacterial profile of each case with every other case
created a matrix of similarity coefficients; therefore, a
mean similarity coefficient for cases could be calculated.
This was done for controls also.
All the other statistical analyses were performed using
SPSS for Windows, version 12.01. Demographic charac-
teristics of cases and controls were compared using w2
tests.
The number of bands for each individual in the total
bacterial profile (band richness) was calculated as an
indicator of diversity of the total microbiota. The mean
Table 1. Primers and probes used in this study
Primer/probe Sequence (50–30) References
968-GC-f CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGC
ACGGGGGG-AACGCGAAGAACCTTA
[19]
1401-r CGGTGTGTACAAGACCC [19]
Bif-164-f GGGTGGTAATGCCGGATG [19, 20]
Bif-662-GC-r CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGG-
CCACCGTTACACCGGGAA
[19, 20]
Bif-f GCGTGCTTAACACATGCAAGTC [24]
Bif-r CACCCGTTTCCAGGAGCTATT [24]
Bif-pr TCACGCATTACTCACCCGTTCGCC [24]
Total-f TCCTACGGGAGGCAGCAGT [35, 36]
Total-r GGACTACCAGGGTATCTAATCCTGTT [35, 36]
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number of bands (band richness) in the total bacterial
profiles was compared between cases and controls using
the Student t-test. Furthermore, bands (in total bacterial
profiles) present in 20 or more infants were compared for
their prevalence in cases and controls using the w2 test.
The Mann–Whitney rank sum-test was used to compare
bifidobacterial counts (expressed as proportion of total
bacterial counts) between cases and controls. To test for
differences in the prevalence of specific bifidobacterial
strains, as shown in the bifidobacterial profiles, the w2 test
was used.
Results
Of the 646 infants who met the selection criteria (presence
of feces, capillary blood, full term birth and no history of
antibiotic use in first month), 26 infants had both devel-
oped eczema in the first year of life along with specific IgE
antibodies against milk, hen’s egg and/or cow’s milk
(4 1 IU/mL). All these infants were included as cases in
the present study. Of the 375 infants who had not devel-
oped eczema in the first year and had no detectable
specific IgE antibodies in their blood, 52 were randomly
selected as controls.
There were no statistically significant differences be-
tween cases and controls in gender, infant feeding, birth
season and mode of delivery (Table 2). However, the cases
more often had an allergic mother (self-reported doctor’s
diagnosed eczema, hayfever, asthma, pet and/or house
dust mite allergy) compared with healthy infants (54%
compared with 14%, P= 0.00) and also, although not
statistically significant, tended to have an allergic father
more often (46% compared with 27%, P= 0.09). To ac-
count for a potential confounding effect of parental atopic
status, all following analyses were performed both un-
stratified and stratified for parental atopic status (at least
one parent atopic vs. none parents atopic).
The number of bands in total bacterial profiles or band
richness represents the number of bacterial species present
in a fecal sample and thus the diversity of the microbiota.
The band richness was similar in cases and controls
(mean; 7.54 vs. 7.63 bands, P = 0.92). Also after stratifica-
tion on parental atopic status (data not shown), no
difference in mean band richness between cases and
controls was found.
Comparison of total bacterial profiles showed that
similarities between individuals were low, with mean
similarity coefficients of 32.5% for cases and 33.7% for
controls.
Five bands in total bacterial profiles were present in 20
or more infants; these bands were tested for difference in
prevalence between cases and controls. One of these bands
was present in all except one of the cases and in only 37 of
52 controls (96% vs. 71%, P= 0.01). This association
persisted after adjusting for parental atopic status. This
particular band had a similar position on gel as did the
Escherichia coli control band from the identification
ladder (Fig. 1). Excising and sequencing of this band from
several lanes confirmed that it represented a fragment that
was derived from the genome of E. coli (Fig. 1). The
prevalence of the other four bands was similar in cases
and controls.
Bifidobacteria were detected in all infants and the
proportion that bifidobacteria comprised of the total
bacterial counts was not significantly different between
cases (median 37.6%, range 0.07% to 4 99%) and con-
trols (median 56.9%, range 0.001% to 4 99%, P= 0.66).
The proportion of bifidobacteria of total bacterial counts
remained similar in cases and controls in stratified ana-
lyses on parental atopic status.
The prevalence of the different bifidobacterial species,
as determined by bifidobacterium-specific DGGE, is
shown in Table 3. B. breve was most frequently detected
(36/78 infants), followed by B. bifidum (32/78 infants).
Table 2. Characteristics of study population
Cases Controls P-value
Boys 17/26 (65%) 24/52 (46%) 0.11
Excl breastfed 21/26 (81%) 37/52 (71%) 0.36
Birth season – – 0.33
Vaginal delivery 20/26 (77%) 44/52 (85%) 0.40
Mother allergic 14/26 (54%) 7/52 (14%) 0.00
Father allergic 12/26 (46%) 14/52 (27%) 0.09
Fig. 1. An example of total bacterial profiles of fecal samples of 1-
month-old infants (1–5) and of an identification ladder (ID), as deter-
mined by denaturing gradient gel electrophoreses. Samples 1, 2 and 4
have a band corresponding to Escherichia coli.
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The prevalence of the different bifidobacterial species was
similar between cases and controls (Table 3), and adjusting
for parental atopic status did not change these results
(data not shown).
Discussion
In the present study, PCR-DGGE was used to examine total
bacterial profiles and the type and proportion of bifido-
bacteria in fecal samples of 1-month-old infants in whom
IgE-associated eczema was or was not going to develop
within the first year of life. Neither total bacterial profiles
nor the type and proportion of bifidobacteria in the
samples were associated with the development of IgE-
associated eczema. E. coli was however significantly more
often detected in infants who were going to develop atopic
eczema compared with healthy controls.
Matching may increase efficiency if matching on strong
risk factors is employed. Valid estimates can, however,
also be obtained by controlling for important confounders
in the analyses. Instead of matching, we therefore chose to
perform stratified analysis on parental atopic status, the
only population characteristic under study which differed
between cases and controls. We found that this stratifica-
tion did not change the results.
It has been suggested that if differences in gut micro-
biota composition truly exist in early life between chil-
dren who go on to develop atopic sensitization compared
with those who do not, it is possible that these differences
are genetically determined [14]. As the association be-
tween E. coli and IgE-associated eczema in our study
persisted after adjusting for parental atopic status, this
explanation seems unlikely. Furthermore, as fecal sam-
pling was conducted before the manifestation of atopic
symptoms, we can conclude that differences in E. coli
colonization precede the development of IgE-associated
eczema.
Kirjavainen et al. [26] reported the number of E. coli in
feces to be positively correlated with total serum IgE levels
in infants with atopic dermatitis. Conversely, oral intro-
duction of a non-enteropathogenic E. coli strain after
birth has been shown to reduce the risk of developing
allergic diseases in another study [27]. It seems therefore
likely that the effects of E. coli are strain-dependent.
Interestingly, administration of probiotic E. coli strains in
the intestine has been shown to decrease the presence of
pathogenic bacterial strains [28], and to enhance the
barrier defense against some pathogenic E. coli strains
[29].
It has been argued that the impact of the indigenous
microbiota on the development of the infant’s immune
system may not be dependent on specific microbial
strains, but that continuing stimulation by the dynamic
microbiota as a whole might override the importance of
any individual strain or infection [30]. For instance, a high
turnover of appropriate bacteria may provide such a
continuous immune stimulation necessary to prevent
atopy and atopic diseases [31]. A lower diversity of the
bacterial microbiota could be related to a limited bacterial
turnover, suggesting to reduce the stimulation of the
immune system [32, 33]. This would imply that atopic
infants have a less diverse microbiota compared with
healthy infants. However, we did not find that cases had
a lower diversity (less bands) than controls. Total bacterial
profiles of both atopic and healthy infants under study
comprised on average seven to eight different bands
indicating a relatively low diversity of the dominant
intestinal microbiota. Indeed, it is known that infants at
this young age have a relatively simple microbiota [34].
Another way to examine if the intestinal microbiota as
a whole is involved in the development of atopic diseases
is by looking at the total bacterial profiles. If infants in
whom IgE-associated eczema is going to develop would
have a predisposing microbial make-up in common early
in life, this would be expressed in a high similarity index.
Mean similarity coefficients in both atopic and healthy
infants were low (approximately 33% in both atopic and
healthy infants), meaning each individual has a fairly
unique bacterial profile already at this age, and we found
no common bacterial profile among infants becoming
atopic.
Although we did not find that the dominant microbiota
as a whole (diversity and similarity) was associated with
the development of IgE-associated eczema, it should be
noted that by using PCR-DGGE only dominant species
(4 1% of total microbiota) can be visualized. Therefore, it
cannot be excluded that differences exist in the number
and profiles of minor species between infants in whom
IgE-associated eczema was or was not going to develop.
Bifidobacteria have been associated with a lower risk of
developing atopic diseases [3, 4, 6, 7]; furthermore,
different bifidobacterial species have been shown to exert
different effects on the immune system [8, 9], and were
differently associated with atopic eczema [10], but not
with IgE-associated wheeze [14]. We found no association
between the proportion bifidobacteria of total counts or
specific bifidobacterial strains and IgE-associated eczema.
The infant-type bifidobacteria (B. breve and B. bifidum)
were most frequently detected, whereas the adult-type B.
Table 3. The composition of the Bifidobacterium population in cases and
controls
Bifidobacterium species Cases Controls P-value
B. breve 15 (58%) 21 (40%) 0.15
B. bifidum 9 (35%) 23 (44%) 0.42
B. infantis/B. longum 3 (12%) 10 (19%) 0.53w
B. adolescentis 0 (0%) 3 (6%) 0.55w
w2 test.
wFisher’s exact test.
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adolescentis, which has previously been linked to allergy
[10], was only detected in three healthy infants in our
study.
In conclusion, we did not find an association between
the dominant gut microbiota as a whole and IgE-asso-
ciated eczema. Already at this young age each infant
appeared to have a unique, although still simple, bacterial
profile. Also, no association was found between the
number of bifidobacteria or the type of bifidobacterial
species and the development of atopy. The development of
IgE-associated eczema was however associated with colo-
nization by E. coli, indicating that differences in gut
microbiota do precede the development of atopy. Larger
differences may be found for those species that are not
part of the dominant microbiota.
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